Luminal B breast carcinoma
MONDO:0021115A biologic subset of breast carcinoma defined by low to moderate expression of genes characteristic of luminal epithelial cells including estrogen receptor (ER), and high expression of GGH, LAPTM4B, and CCNE1. This subtype of breast cancer is associated with a good prognosis, although not as favorable as the luminal A subtype.
Also known as: Luminal B, Luminal B breast cancer, Luminal B breast carcinoma, Luminal B estrogen receptor positive subtype of breast carcinoma, Luminal B oestrogen receptor positive subtype of breast carcinoma, Luminal B subtype of breast carcinoma
2802 clinical trials for this condition and its sub-types, 8 tagged with Luminal B breast carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Promising breast cancer drug trial pulled before starting
Disease control CancelledThis study aimed to see if the drug trastuzumab deruxtecan worked better than standard CDK4/6 inhibitors for people with a specific advanced breast cancer (ER-positive, HER2-low, non-luminal A). It was designed for adults with metastatic disease. However, the trial was withdrawn …
Phase 3 • Sponsor: Danish Breast Cancer Cooperative Group • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Real-World data may reveal which breast cancer subtype responds best to CDK4/6 inhibitors
Knowledge-focused OngoingThis study looks back at medical records of 300 people with metastatic luminal A or luminal B breast cancer who were treated with CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib). The goal is to see how long patients lived without their cancer getting worse, and whethe…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC